Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated — RVF

Rift Valley Fever Clinical Trial

Official title:
Long-Term Open-Label Primary Vaccination and Booster Dose Study of the Safety and Immunogenicity of Rift Valley Fever Vaccine, Inactivated, Dried (TSI-GSD 200) in At-Risk Adults

Status Completed

Clinical Trial Summary

This study is designed to determine the safety and immunogenicity of an inactivated Rift Valley Fever (RVF) Vaccine in adults

Clinical Trial Description

The primary objectives are to assess safety of Rift Valley Fever (RVF) Vaccine, Inactivated (TSI-GSD 200) and to assess immunogenicity of Rift Valley Fever (RVF) Vaccine, Inactivated (TSI-GSD 200). The secondary objective is to assess incidence of RVF infection in vaccinated personnel ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00869713
Study type	Interventional
Source	U.S. Army Medical Research and Development Command
Contact
Status	Completed
Phase	Phase 2
Start date	September 2009
Completion date	May 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05139524` - RVF and Other Emerging Infectious Diseases in East and Central Africa
Recruiting	`NCT03609398` - Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine	Phase 2
Completed	`NCT04672824` - A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults	Phase 1
Completed	`NCT00287014` - Rift Valley Fever in Kenya	N/A
Completed	`NCT00584194` - Safety and Immunogenicity Study of Rift Valley Fever Vaccine	Phase 2
Completed	`NCT04754776` - Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)	Early Phase 1
Completed	`NCT00415051` - Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine	Phase 2